Quick Answer
Serina Therapeutics, Inc. reported R&D Expense of $13.15 million for fiscal year 2025.
Serina Therapeutics, Inc. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $13.15M | +75.9% |
| 2024 | $7.48M | +213.2% |
| 2023 | $2.39M | +133.0% |
| 2022 | $1.02M | -29.6% |
| 2021 | $1.46M | -60.8% |
| 2020 | $3.71M | -37.1% |
| 2019 | $5.90M | +1.3% |
| 2018 | $5.83M | +0.8% |
| 2017 | $5.78M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.65M | +51.2% | +15.8% |
| June 30, 2025 | $3.15M | +97.7% | +6.8% |
| March 31, 2025 | $2.95M | +166.8% | +22.2% |
| September 30, 2024 | $2.42M | +300.5% | +51.5% |
| June 30, 2024 | $1.59M | +232.8% | +44.1% |
| March 31, 2024 | $1.11M | +177.2% | +83.4% |
| September 30, 2023 | $603.0K | +272.2% | +25.9% |
| June 30, 2023 | $479.0K | +84.9% | +20.1% |
- Serina Therapeutics, Inc. showed an increase of +75.9% in R&D Expense compared to the prior fiscal year.
- Over the 2017–2025 period, Serina Therapeutics, Inc.’s r&d expense has grown by 127.4% (from $5.78 million to $13.15 million).
- The most recent figure is from Serina Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: